Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
2 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
29 Nov 23
424B5
Prospectus supplement for primary offering
29 Nov 23
424B5
Prospectus supplement for primary offering
28 Nov 23
8-K
Other Events
13 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Other Events
23 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Entry into a Material Definitive Agreement
15 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
S-8
Registration of securities for employees
2 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
2 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Feb 23
8-K
Other Events
5 Dec 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7 Nov 22
S-3ASR
Automatic shelf registration
23 Sep 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
9 Aug 22
8-K
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
21 Jul 22
424B5
Prospectus supplement for primary offering
21 Jul 22
8-K
Other Events
21 Jul 22
424B5
Prospectus supplement for primary offering
20 Jul 22
8-K
Entry into a Material Definitive Agreement
20 Jul 22
EFFECT
Notice of effectiveness
13 Jul 22
8-K
Other Events
12 Jul 22
Latest ownership filings
4
Joan Nickerson
3 Apr 24
4
Andrew D. Ashe
16 Feb 24
4
Sekar Kathiresan
16 Feb 24
4
Joan Nickerson
16 Feb 24
4
Fred T. Fiedorek
16 Feb 24
4
Allison Dorval
16 Feb 24
4
Andrew Bellinger
16 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
5
BURT A ADELMAN
9 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
SC 13G/A
GV 2017, L.P.
11 Dec 23
SC 13G/A
FMR LLC
11 Dec 23
3
Initial statement of insider ownership
5 Dec 23
4
Krishna Yeshwant
5 Dec 23
4
Allison Dorval
1 Dec 23
4
Fred T. Fiedorek
19 Sep 23
3
Fred T. Fiedorek
19 Sep 23
4
Michael F MacLean
20 Jun 23
4
Alexander Cumbo
20 Jun 23
4
Krishna Yeshwant
20 Jun 23
4
BURT A ADELMAN
20 Jun 23
4
LONNEL COATS
20 Jun 23
4
Sheila Mikhail
20 Jun 23
3
Joan Nickerson
23 Feb 23
4
Andrew Bellinger
16 Feb 23
4
Allison Dorval
16 Feb 23
4
Sekar Kathiresan
16 Feb 23
4
Michael F MacLean
16 Feb 23
4
Andrew D. Ashe
16 Feb 23
SC 13G/A
SINGER JAMES R
14 Feb 23
SC 13G/A
Casdin Capital, LLC
13 Feb 23
SC 13G/A
ARCH Venture Fund X, L.P.
13 Feb 23
SC 13G/A
GV 2017, L.P.
10 Feb 23
SC 13G
BlackRock Inc.
10 Feb 23
SC 13G
ARK Investment Management LLC
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G
VANGUARD GROUP INC
9 Feb 23
SC 13G
STATE STREET CORP
7 Feb 23